Zhang, Youyan

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Ryan, M. B., Coker, O., Sorokin, A., Fella, K., Barnes, H., Wong, E., Kanikarla, P., Gao, F., Zhang, Y., Zhou, L., et al. (2022) · Cell Reports

Protein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

Cited by 177

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

Chen, S.-H., Zhang, Y., Van Horn, R. D., Yin, T., Buchanan, S., Yadav, V., Mochalkin, I., Wong, S. S., Yue, Y. G., Huber, L., et al. (2016) · Cancer Discovery

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 171

A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes

Liang, Y., Lin, S., Beyer, T. P., Zhang, Y., Wu, X., Bales, K. R., DeMattos, R. B., May, P. C., Li, S. D., Jiang, X., et al. (2004) · Journal of Neurochemistry

Cholesterol and Lipid MetabolismAlzheimer's disease research and treatments

Cited by 160

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysAdvanced Breast Cancer Therapies

Cited by 132

Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models

Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., et al. (2026) · Nature Communications

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 1